CNTO-328 Centocor

Current Opinion in Investigational Drugs

Volumn 6, Issue 6, 2005, Pages 639-645

  Li, Jie ^a   Hu, Xiu Feng ^a   Xing, Pei Xiang ^a  

^a AUSTIN RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CNTO 328; CREATININE; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR; STEROID;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CANCER INHIBITION; CLINICAL TRIAL; DISEASE MODEL; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG INDICATION; DRUG INFUSION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; GRANULOCYTOPENIA; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; MAXIMUM TOLERATED DOSE; MELANOMA; NONHUMAN; PATENT; PNEUMONIA; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVIEW; SEPTICEMIA; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; URINARY TRACT INFECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; INTERLEUKIN-6; NEOPLASMS;

EID: 20744438364     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. 193641 Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies. van Zaanen HCT, Koopmans RP, Aarden LA, Rensink HJA, Stouthard JML, Warnaar SO, Lokhorst HM, van Oers MHJ BLOOD 1995 86 10 Suppl 1 Abs 727
2. 274278 IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhardt JA, Janakiraman N, Foon KA, Liles T, Dallaire BK, Way K et al BLOOD 1997 90 6 2188-2195
3. 320341 Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ J CLIN ONCOL 1998 16 8 2659-2671
4. 338611 Annual Report 1998 - Centocor. Centocor Inc ANNUAL REPORT 1998 December 31
5. 465040 Immunomodulating IL-6 activity by murine monoclonal antibodies. Brochier J, Legouffe E, Liautard J, Gaillard JP, Mao LQ, Bataille R, Rossi JF, Klein B INT J IMMUNOPHARMACOL 1995 17 1 41-48
6. 491579 CNTO 328, a potent antibody to interleukin 6 inhibits human cancer cachexia in nude mice. Zaki MH, Trikha M PROC AM SOC CLIN ONCOL 2003 22 Abs 697
7. 515773 Serum amyloid A (SAA), a new tumor derived biomarker for CNTO 328, an anti IL-6 therapy for renal cell carcinoma. Zaki MH, Nemeth J, Mount S, Trikha M CLIN CANCER RES 2003 9 16 Suppl 1 Abs B232
8. 532626 Inhibition of tumor-derived serum amyloid A (SAA) by CNTO 328, an antibody to IL-6. Zaki MH, Nemeth J, Mount S, Trikha M PROC AM ASSOC CANCER RES 2004 45 Abs 4687
9. 535932 IL-6 in auto-immune diseases; emerging therapeutic benefits of IL-6 blockade. Manning A SMI CONF - ANTI-ARTHRITIC AGENTS 2004 April 26-27
10. 542091 Correlation of serum CNTO 328-anti IL-6 monoclonal antibody (mAb) concentrations and biomarker expression in renal cell carcinoma (RCC) patients. Prabhakar U, Jang H, Jiao Q, Ford J, Miller BE, Graham MA, Davis HM PROC AM SOC CLIN ONCOL 2004 23 Abs 2560
11. 542824 American Society of Clinical Oncology - 40th Annual Meeting (Part V) - Overnight Report, New Orleans, LA, USA. Harrison R IDDB MEETING REPORT 2004 June 05-08
12. 545328 Pharmacokinetic/pharmacodynamic (PK/PD) modeling and trial simulations to guide dose selection with CNTO 328, a chimeric anti-IL-6 monoclonal antibody (mAb), in patients with renal cell carcinoma (RCC). Jang H, Prabhakar U, Jiao Q, Ford J, Miller BE, Davis HM, Graham MA PROC AM SOC CLIN ONCOL 2004 23 Abs 2608
13. 553944 Anti-Cancer Drug Discovery and Development - Strategic Research Institute's Sixth Annual Summit, Philadelphia, PA, USA. Zhu Z, Williams B IDDB MEETING REPORT 2004 July 21-23
14. 560046 Monoclonal Antibodies in Cancer - Fourth International Congress (Part II), Colorado Springs, CO, USA. Zhu Z IDDB MEETING REPORT 2004 Sept 03-06
15. 562904 Pharmacokinetics of CNTO 328 in a three month intravenous dose toxicity study in cynomolgus monkeys with concomitant IL-2 therapy. Jiao Q, Prabhakar U, Frigo M, Lohr T, Comacoff J, Davis H, Graham M EUR J CANCER SUPPL 2004 2 8 Abs 184
16. 577997 Antibody Therapeutics - IBC's Second Annual International Conference (Part II), Advances and Strategies of the Development of Antibody Therapeutic Pipeline, San Diego, CA, USA. IDdb author IDDB MEETING REPORT 2005 Nov 30-Dec 03
17. 581536 PK modeling and simulations of an anti II-6 mAb in patients with renal cell carcinoma. Jiao Q, Jang H, Prabhakar U, Ford J, Miller B, Davis HM, Graham MA CLIN PHARMACOL THER 2004 75 2 84
18. 581538 Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: A review of the rationale and clinical evidence. Trikha M, Corringham R, Klein B, Rossi J-F CLIN CANCER RES 2003 9 13 4653-4665
19. 581541 CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Zaki MH, Nemeth A Trikha M INT J CANCER 2004 111 4 592-595
20. 582792 Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: A phase I dose-escalating study. van Zaanen HC, Lokhorst HM, Aarden LA, Rensink HJ, Wamaar SO, van der Lelie J, van Oers MH BR J HAEMATOL 2005 102 3 783-790
21. 593620 Advances in interleukin-6 therapy. Ogata A, Nishimoto N, Yoshizaki K RINSHO BYORI 1999 47 4 321-326.
22. 593622 PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells. Lentzsch S, Chatterjee M, Gries M, Bommert K, Gollasch H, Dorken B, Bargou RC LEUKEMIA 2004 18 11 1883-1890
23. 593623 The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Kallen KJ BIOCHIM BIOPHYS ACTA 2002 1592 3 323-343
24. 593626 Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. Bataille R, Jourdan M, Zhang XG, Klein B J CLIN INVEST 1989 84 6 2008-2011
25. 593628 Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumour cell mass parameters in multiple myeloma. Solary E, Guiguet M, Zeller V, Casasnovas RO, Caillot D, Chavanet P, Guy H, Mack G AM J HEMATOL 1992 39 3 163-171
26. 593635 Autocrine interleukin-6 production and highly malignant multiple myeloma: Relation with resistance to drug-induced apoptosis. Frassanito MA, Cusmai A, Iodice G, Dammacco F BLOOD 2001 97 2 483-489
27. 593637 A novel mature B-cell line (DOBIL-6) producing both parathyroid hormone-related protein and interleukin-6 from a myeloma patient presenting with hypercalcaemia. Ohmori M, Nagai M, Fujita M, Dobashi H, Tasaka T, Yamaoka G, Kawanishi K, Taniwaki M, Takahara J BR J HEMATOL 1998 101 1 688-693
28. 593642 RANK ligand and osteoprotegerin in myeloma bone disease. Sezer O, Heider U, Zavrski I, Kuhne CA, Hofbauer LC BLOOD 2003 101 6 2094-2098
29. 593647 Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Chauhan D, Li G, Podar K, Hideshima T, Mitsiades C, Schlossman R, Munshi N, Richardson P, Cotter FE, Anderson KC BLOOD 2004 104 8 2458-2466
30. 593648 CD130 rather than CD126 expression is associated with disease activity in multiple myeloma. Barille S, Thabard W, Robillard N, Moreau P, Pineau D, Harousseau JL, Bataille R, Amiot M BR J HEMATOL 1999 106 2 532-535
31. 593654 Expression of the interleukin 6 receptor in primary renal cell carcinoma. Costes V, Liautard J, Picot MC, Robert M, Lequeux N, Brochier J, Baldet P, Rossi JF J CLIN PATHOL 1997 50 10 835-840
32. 593656 Autocrine interleukin-6 production in renal cell carcinoma: Evidence for the involvement of p53. Angelo LS, Talpaz M, Kurzrock R CANCER RES 2002 62 3 932-940
33. 593658 Mutations of the p63 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas. Oda H, Nakatsuru Y, Ishikawa T CANCER RES 1995 55 3 658-662
34. 593659 Alleviation of cancer anorexia and cachexia: Studies of the Mayo Clinic and the North Central Cancer Treatment Group. Loprinzi CL, Ellison NM, Goldberg RM, Michalak JC, Burch PA CANCER RES 1990 17 6 Suppl 9 8-12
35. 593662 Biology of cachexia. Tisdale MJ J NATL CANCER INST 1997 89 23 1763-1773
36. 593664 Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Blay JY, Rossi JF, Wijdenes J, Menetrier-Caux C, Schemann S, Negrier S, Philip T, Favrot M INT J CANCER 1997 72 3 424-430
37. 593667 Structure-function analysis of human IL-6. Epitope mapping of neutralizing monoclonal antibodies with amino- and carboxyl-terminal deletion mutants. Brakenhoff JP, Hart M, De Groot ER, Di Padova F, Aarden LA J IMMUNOL 1990 145 2 561-568
38. 593815 CNTO 328, an anti-interleukin-6 (IL-6) antibody, prevents conversion of the LuCaP 35 prostate cancer xenograft to androgen independence in orchiectomized mice. Wallner LP, Dai J, Zhang J, Yao Z, Lu Y, Zaki MH, Trikha M, Keller ET PROC AM ASSOC CANCER RES 2005 46 Abs 966
39. 594343 Monoclonal antibodies as effective therapeutic agents for solid tumors. Hinoda Y, Sasaki S, Ishida T, Imai K CANCER SCI 2004 95 8 621-625
40. 595045 Tocilizumab, humanized anti-human IL-6 receptor monoclonal antibody, approved for manufacturing in Japan. Chugai Pharmaceutical Co Ltd PRESS RELEASE 2005 April 13
41. 597386 The interleukin-6 receptor α-chain (CD126) is expressed by neoplastic but not normal plasma cells. Rawstron AC, Fenton JA, Ashcroft J, English A, Jones RA, Richards SJ, Pratt G, Owen R, Davies FE, Child JA, Jack AS, Morgan G BLOOD 2000 96 12 3880-3886
42. 597387 Expression of IL-6 and IL-6 receptors by circulating clonotypic B cells in multiple myeloma: Potential for autocrine and paracrine networks. Szczepek AJ, Belch AR, Pilarski LM EXP HEMATOL 2001 29 9 1076-1081